Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Liabilities (2018 - 2025)

Historic Total Liabilities for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $655.0 million.

  • Revolution Medicines' Total Liabilities rose 23301.1% to $655.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $655.0 million, marking a year-over-year increase of 23301.1%. This contributed to the annual value of $293.1 million for FY2024, which is 2445.15% up from last year.
  • Revolution Medicines' Total Liabilities amounted to $655.0 million in Q3 2025, which was up 23301.1% from $564.2 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Total Liabilities registered a high of $655.0 million during Q3 2025, and its lowest value of $89.0 million during Q2 2021.
  • Over the past 5 years, Revolution Medicines' median Total Liabilities value was $144.5 million (recorded in 2022), while the average stood at $208.5 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 815.82% in 2023, then skyrocketed by 23301.1% in 2025.
  • Quarter analysis of 5 years shows Revolution Medicines' Total Liabilities stood at $135.4 million in 2021, then fell by 6.41% to $126.7 million in 2022, then surged by 85.82% to $235.5 million in 2023, then grew by 24.45% to $293.1 million in 2024, then soared by 123.48% to $655.0 million in 2025.
  • Its last three reported values are $655.0 million in Q3 2025, $564.2 million for Q2 2025, and $287.2 million during Q1 2025.